Patents by Inventor Nikhil C. Munshi

Nikhil C. Munshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230248769
    Abstract: This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.
    Type: Application
    Filed: October 31, 2022
    Publication date: August 10, 2023
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C Anderson
  • Patent number: 11517591
    Abstract: This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: December 6, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Publication number: 20220118018
    Abstract: This disclosure relates to T cell receptors (e.g., T cell receptors comprising alpha chains and beta chains) specific to B-cell maturation antigen (BCMA), T cells comprising same, and methods of use thereof.
    Type: Application
    Filed: March 5, 2020
    Publication date: April 21, 2022
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Publication number: 20220031821
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in WIC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: July 8, 2021
    Publication date: February 3, 2022
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Patent number: 11083783
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 10, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Publication number: 20200352995
    Abstract: This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.
    Type: Application
    Filed: August 31, 2018
    Publication date: November 12, 2020
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Patent number: 9950047
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: April 24, 2018
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Patent number: 9770497
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: September 26, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Publication number: 20160008444
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: June 29, 2015
    Publication date: January 14, 2016
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Publication number: 20150297695
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: November 5, 2013
    Publication date: October 22, 2015
    Inventors: Jooeun Bae, Nikhil C. Munshi, Kenneth C. Anderson
  • Patent number: 9096681
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: August 4, 2015
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Publication number: 20110159021
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: June 1, 2009
    Publication date: June 30, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • Publication number: 20090068210
    Abstract: Methods and compositions for treating, preventing and/or managing various hematological malignancies are disclosed. Specific methods and compositions relate to use of tumor cells engineered to express antigen presenting molecules which present antigens recognized by iNKT cells and eliciting antitumor immune response from iNKT cells using such tumor cells, optionally in combination with an immunomodulatory compound.
    Type: Application
    Filed: July 8, 2008
    Publication date: March 12, 2009
    Inventors: Nikhil C. Munshi, Weihua Song, Mark A. Exley
  • Publication number: 20040101836
    Abstract: Methods, apparatus, compositions, and products for screening and/or treating cancer in a patient are disclosed. Methods, apparatus, compositions, and products comprise a stathmin/oncoprotein 18 sequence. The sequence of the invention may be a single stranded nucleic acid,a double stranded nucleic acid, a polypeptided, an antibody, an oligonucelotide, or any combination thereof.
    Type: Application
    Filed: December 3, 2001
    Publication date: May 27, 2004
    Inventors: Nikhil C. Munshi, Jing Yi Wang